Published in final edited form as:

Sci Transl Med. 2012 July 18; 4(143): 143ra98. doi:10.1126/scitranslmed.3003984.

Rapid Evolution of HIV-1 to Functional CD8⁺ T-Cell Responses in Humanized BLT Mice

Timothy E. Dudek¹, Daniel C. No¹, Edward Seung², Vladimir D. Vrbanc², Lena Fadda¹, Priyasma Bhoumik¹, Christian L. Boutwell¹, Karen A. Power¹, Adrienne D. Gladden¹, Laura Battis¹, Elizabeth F. Mellors¹, Trevor R. Tivey², Xiaojiang Gao³, Marcus Altfeld¹, Andrew D. Luster², Andrew M. Tager², and Todd M. Allen^{1,*}

¹Ragon Institute of MGH, MIT, and Harvard, Charlestown, MA, USA

²Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA

³Cancer and Immunology Program, Laboratory of Experimental Immunology, SAIC Frederick, NCI Frederick, Frederick, MD, USA

Abstract

Important advancements in the development of novel mouse/human chimeras through the engraftment of human immune cells and tissues into immunodeficient mice, including the recently described humanized BLT mouse model, holds great promise to facilitate the *in vivo* study of human immune responses. However, little data exists regarding the extent to which cellular immune responses in humanized mice accurately reflect those seen in humans. As a model pathogen we infected humanized BLT mice with HIV-1 and characterized HIV-1-specific immune responses and viral evolution during the acute phase of infection. HIV-1-specific CD8⁺ T cell responses in these mice were found to closely resemble those in humans in terms of their specificity, kinetics and immunodominance. Viral sequence evolution also revealed rapid and highly reproducible escape from these responses, mirroring the adaptations to host immune pressures observed during natural HIV-1 infection. Moreover, mice expressing the protective HLA-B*57 allele exhibited enhanced control of viral replication, and restricted the same CD8⁺ T cell responses to conserved regions of HIV-1 Gag that are critical to its control of HIV-1 in humans. These data reveal that the humanized BLT mouse model appears to accurately recapitulate human pathogen-specific cellular immunity and the fundamental immunological mechanisms required to control a model human pathogen, aspects critical to the utility of a small animal model for human pathogens.

Introduction

Animal models are critical to our understanding of human pathogens and diseases. The capacity to monitor, induce and augment immune responses in animal models has been

*Corresponding Author: Todd M. Allen, Ragon Institute of MGH, MIT and Harvard, Mass. General Hospital - East, Bldg 149 13th Street, Charlestown, MA 02129, tallen2@partners.org, Tel: 617-726-7846.

Author contributions: T.D., C.B. E.S., A.T., V.V. and T.A. designed experiments; T.D. and T.A. wrote the manuscript; T.D. and D.N. produced virus and quantified viral loads; T.D., D.N., E.M., K.P., A.G., and L.B. assisted with sequencing reactions and analysis; A.T., E.S., V.V. and T.T. produced, infected and drew samples from the mice; L.F. performed flow-cytometry; P.B. assisted with statistical analysis; X.G. provided HLA analysis; M.A., A.L., A.T. and T.A. provided funding.

Competing interests: The authors have no competing, nor financial interests regarding the studies or results described in this manuscript.

integral to the development of novel therapeutics and vaccines. However, many human pathogens do not successfully infect typical laboratory animal species, requiring the extrapolation of data acquired from models of pathogens similar, but not identical, to those infecting humans. In the case of HIV-1, the model of choice is the SIV-infected rhesus macaque, which has proven invaluable for studying the mechanisms of disease pathogenesis and vaccine efficacy (1, 2). Nonetheless, differences in host genetics between humans and macaques, particularly in their MHC class I alleles and T-cell receptor repertoire, as well as substantial sequence differences between HIV-1 and SIV, prevent the study of HIV-1-specific human immune responses in macaques. Additionally, while studies of genetically similar macaques or identical subjects can facilitate a more stringent interpretation of data (3, 4) the inherent genetic diversity among macaques typically complicates the interpretation of experimental results. Thus, improved animal models that are capable of more accurately modeling natural human immune responses to HIV-1 infection, and can exhibit a high degree genetic homogeneity, could substantially accelerate biomedical research and vaccine development for HIV-1 as well as a number of other human pathogens (5, 6).

The recent generation of humanized BLT (bone marrow, liver, thymus) mice, through the implantation of human fetal thymic and liver tissues along with the transfer of human fetal liver-derived CD34⁺ hematopoietic stem cells (HSCs), has dramatically improved the ability of mice to support human immune system reconstitution. In these BLT mice, human T-cells may become educated within autologous human thymic tissues, rather than within xenogenic mouse tissues, resulting in a significantly more robust repopulation of human immune cells. While these and other humanized mice have been shown to develop cellular immune responses against pathogens and/or immunogens (7-12), little evidence of the specificity or the functionality of these responses exist, nor of the ability of these responses to control infections. Therefore, the extent to which cellular immune responses in these animals accurately reflect those seen during natural human infection and exhibit control of pathogens remains unclear.

While humanized BLT mice support sustained levels of HIV-1 replication (8, 13, 14) reports describing the development of HIV-1 specific cellular immune responses have been inconsistent, with some groups detecting responses (8, 11) while others note a paucity of detectable responses (13, 15). Here we detected and characterized CD8⁺ T-cell responses and early viral sequence evolution against this model pathogen. Our results indicate that the kinetics, magnitude, specificity and immunodominance hierarchies of human HIV-1-specific CD8⁺ T-cell responses mounted in humanized BLT mice during the acute phase of infection appear to closely resemble those of HIV-1 infected humans. Notably, viral escape from these responses was also rapid and highly reproducible, supportive of their ability to exhibit anti-viral effects and of HIV-1 to evolve under similar pathways. More importantly, BLT mice expressing the protective allele HLA-B*57 mounted the same Gag-specific CD8⁺ T-cell responses typical of B*57-positive elite controller subjects and exhibited enhanced control of HIV-1, further supporting the ability of this model to recapitulate critical mechanisms of immune control over HIV-1.

Results

Human immune system reconstitution in BLT mice allows for productive infection with HIV-1

Eight groups of either gamma-irradiated NOD/SCID-BLT (NS-BLT) or NOD/SCID/IL2R $\gamma_c^{-/-}$ -BLT (NSG-BLT) mice were transplanted with individual human donor liver and thymus tissue expressing distinct HLA haplotypes (Table 1), followed by injection of CD34⁺ hematopoietic stem cells as previously described (8). Sufficient reconstitution with human immune cells (see Materials and Methods) usually occurred between 12 and 20

weeks after surgery, with NSG-BLT mice often reconstituting by 12-14 weeks after surgery, while NS-BLT mice required 16-20 weeks after surgery for sufficient reconstitution (Table S1). This difference in reconstitution kinetics between NS-BLT and NSG-BLT mice has been previously described (16). Mice were then infected with 1×10^5 TCID₅₀ of HIV-1 JR-CSF molecular clone via the intraperitoneal route.

Evolution of HIV-1 in humanized BLT mice occurs predominantly within CD8⁺ T-cell epitopes

Due to the ability of HIV-1 to reproducibly escape from CD8⁺ T-cell responses in humans (17-20), we first looked for evidence of viral sequence evolution in BLT mice as a surrogate marker of immune activity. Full-length bulk sequencing of plasma-derived virus in three group M20 mice expressing HLA-A*01/A*02, B*08/B*52, and C*03/C*07 revealed considerable viral sequence diversity in each mouse by 6 weeks post-infection (p.i.) (Fig. S1). This early sequence evolution was predominated by non-synonymous mutations, with 7 of these 25 non-synonymous substitutions located within the 31 well-defined CD8⁺ T-cell epitopes restricted by the donor's HLA alleles (21). Given that these 31 CD8 epitopes constitute only a small fraction of the total viral genome, early amino acid mutations in the BLT mice were thus found to arise disproportionately within the donor's restricted CD8 epitopes (OR = 4.50, 95% CI = 1.86-10.88; $p = 0.003$). In particular, reproducible viral evolution was observed in the epitopes Env A*01-RY9 (RRGWEILKY) and Nef C*03-AL9 (AAIDLSHFL), each of which evolved within two of the three M20 mice.

To conduct a more thorough analysis of early viral evolution we cloned and sequenced a 908bp stretch spanning these two Env and Nef CD8 epitopes from six M20 mice at two time points between 6 and 12 weeks post-infection (p.i.). While clones derived from the infecting JR-CSF viral stock were identical, clones derived from five out of six mice exhibited a clear pattern of mutations across both the Env A*01-RY9 and Nef C*03-AL9 epitopes (21). Viral evolution was also observed within a less commonly targeted Env A*02-LL9 (LLQYWSQEL) epitope (22, 23) (Fig. 1A; see Fig. S2A for both time points). Thus, viral escape from CD8⁺ T-cell responses appears to be rapid and highly reproducible, suggesting that multiple CD8⁺ T-cell responses are developing normally in humanized BLT mice following HIV-1 infection.

Viral escape pathways in genetically identical humanized BLT mice is reproducible

During viral escape from CD8⁺ T-cell responses in HIV-1 infection the selection and outgrowth of specific mutations is influenced by the differential capacities of mutations to achieve efficient CTL escape while minimizing the impact on viral protein structure and function (24-27). A closer examination of amino acid substitutions within the three evolving CD8 epitopes revealed that similar, albeit not identical, pathways of viral escape were employed between the different M20 mice (Fig. 2A). In the Env A*01-RY9 epitope, amino acid positions 1 (P1) and 5 (P5) exhibited the highest frequencies of mutations, with a P1 arginine to histidine substitution predominating. In the Nef C*03-AL9 epitope, mutations were observed predominately at positions 3, 4 and 5 with the P3 leucine and P4 asparagine notably representing 100% of the clones by week 12 in M20-25 and M20-16, respectively. Even in the subdominant Env A*02-LL9 epitope evolution was limited to a P6 serine to glycine substitution in mice M20-16 and M20-27. Thus, similar forces appear to limit the possible pathways of viral escape from CD8⁺ T-cell responses in BLT mice.

HLA class I-associated evolution is consistent across mice expressing distinct HLA haplotypes

To further explore whether HLA-specific adaptations were reproducible across mice reconstituted from distinct human donor tissues but sharing the same HLA allele we infected

mice from three additional engraftments (M16-22, M24-15 and M33-07) sharing one or more of the M20 HLA alleles (Table 1). Viral evolution in the Env A*01-RY9 epitope was limited to the A*01-expressing mouse M16-22, while evolution in the Nef C*03-AL9 epitope was limited to one of the two C*03-expressing mice, M33-07 (Fig. 1B and 2B). Examination of the 4-digit HLA typing revealed that while M33-07 expressed C*03:03 (identical to group M20), M24-15 expressed C*03:04 supporting the possibility that the restriction of this response may be specific to the expression of C*03:03.

In examining viral evolution across all infected mice, there was a statistically significant increase in the presence of non-synonymous mutations in both the Env A*01-RY9 and Nef C*03-AL9 epitopes in mice expressing the respective restricting HLA allele ($p < 0.001$), demonstrating the HLA-associated selection of these mutations. This effect remained significant for the Nef C*03-AL9 epitope even when mouse M24-15 (C*03:04) was included in the analysis ($p = 0.004$). These data demonstrate that the viral evolution observed is not random, but rather restricted to the expression of a specific HLA class I allele.

Early HIV-1 sequence evolution is susceptible to stochastic events and is partially driven by human APOBEC3G/F activity

Early inpatient HIV-1 sequence diversity, prior to the onset of adaptive immune pressures, is largely stochastic (28, 29). This is mediated in part through the random error-prone nature of reverse transcription (30, 31), as well as the cytidine deaminase hypermutation effects of the host factor APOBEC3G/F (32). Notably, 39% of all nucleotide mutations (112/286) in BLT mice within these first few weeks after infection reflected G-to-A substitutions, typical of APOBEC3G/F activity, with 21% of mutations (60/286) exhibiting characteristic signatures of human APOBEC3G/3F hypermutation (33) (Fig. S2B). This includes many of the mutations observed in the escaping CD8 epitopes, such as those in the Env A*01-RY9 epitope in M20-22 at week 6, and in the Nef C*03-AL9 epitope in M20-16 at week 12. These data support that the intrinsic ability of infected human CD4⁺ T-cells to inhibit viral replication capacity through human APOBEC3G/F proteins (34) shown in another humanized mouse model (35) is also conserved in this humanized BLT mouse model.

Epitope-specific CD8⁺ T-cell responses are detectable in BLT mice

The predominant selection of mutations in the Env A*01-RY9 and Nef C*03-AL9 epitopes suggested that these regions of the virus were under strong immune selection pressures. Utilizing epitope-specific T-cell lines stimulated for 2-3 weeks, responses to each of these CD8 epitopes in M20 mice were detected using IFN- γ ELISpot assays (Fig. 3A) and the CD8 restriction of the Env T-cell line was confirmed through intracellular IFN- γ cytokine staining (Fig. 3B). More importantly, peptides representing the predominant mutations observed in each epitope were found to significantly impair immune recognition, with the most commonly observed P1 histidine and P3 leucine mutations in Env A*01-RY9 and Nef C*03-AL9, respectively, nearly completely impairing CD8⁺ T-cell recognition (Figs. 3C, D). These data confirm that this rapid evolution of HIV-1 in the BLT mice reflects active evasion from human CD8⁺ T cell responses.

BLT mice expressing HLA-B*57 restrict the same immunodominant CD8 epitopes seen in acutely infected humans

Particular HLA class I alleles, such as HLA-B*57, exhibit the ability to naturally control HIV-1 through the predominant targeting of the highly conserved Gag protein (36-39). To examine whether such critical immune responses restricted by protective HLA alleles in humans are also accurately reflected in humanized BLT mice, we employed two groups of

BLT mice (M31 and M51) reconstituted with tissues expressing HLA-B*57 (Table 1). Here *ex vivo* IFN- γ ELISpot responses were detected with the addition of immortalized, isogenic B-cell lines (Fig. S3, (40-42)). At 10 weeks p.i. M31 mice exhibited detectable *ex-vivo* CD8⁺ T-cell responses against the immunodominant B*57-restricted epitopes Gag-IW9, -KF11 and -TW10 as well as Rev-KY10 and Nef-KF9 (21). Responses to each epitope were on the order of 200 - 600 SFC/million PBMC (Fig. 4A), magnitudes that are in line with responses observed in HLA-B*57 positive, untreated, chronically infected humans (43). Development of these HLA-B*57 restricted responses was confirmed in the M51 mice by ELISpot assay at weeks 8, 10 and 12 p.i. (Fig. 4B) and by MHC-I tetramer staining of the KF11-specific response at 12 weeks p.i. (Fig. 4C).

Clonal sequencing of four M31 mice in these regions of Gag, Rev and Nef at 10 weeks p.i. revealed reproducible patterns of rapid viral evolution in the targeted Rev-KY10 and Nef-KF9 epitopes. In contrast, there was a notable lack of escape in the three Gag epitopes. We also observed reproducible evolution in all 4 mice within a short region of Vpu (Fig. 5). Although this region of Vpu does not contain any described CD8 epitopes for the HLA alleles expressed by the M31 mice, it is consistent with an HLA-B*57 binding motif (X-(ATS)-X-X-X-X-X-X-(FW)), and prior studies of human cellular immune responses have shown that 2 of 4 individuals that responded to this region of Vpu expressed HLA-B*57 (44, 45). These observations are in line with the kinetics of viral escape observed in these epitopes in humans, with rapid escape in the Rev and Nef epitopes (46), but delayed escape from the more functionally constrained Gag epitopes (45, 47-49). Additionally, there were few if any mutations observed within well-defined CD8 epitopes restricted by other HLA molecules expressed in the mice, suggesting that the immunodominance of HLA-B*57 restricted responses over other restricted responses (43, 50) may be recapitulated in the BLT mice. Taken together, these data suggest that the Gag-specific CD8⁺ T-cell responses critical to the control of HIV-1 in B*57 positive humans, and the sequence constraints that limit the ability of HIV-1 to rapidly escape from these responses, are accurately reproduced in humanized BLT mice.

Expression of HLA-B*57 in BLT mice is associated with stronger suppression of plasma viremia

Finally, we examined whether the ability of particular HLA alleles to exhibit control over HIV-1 might also be reproduced in this model. We first examined plasma viral loads in four groups of mice expressing common HLA alleles not associated with control of HIV-1 viremia (M20, M24, M30 and M47; 15-28 mice per time point). Viral loads in these mice were markedly consistent over time, exhibiting peak viral loads and set-points greater than 1×10^5 copies/ml (Fig. 6) and a dip in viremia around 4 weeks p.i. We observed no significant difference in viral load set point among these mice. In contrast, viral loads in two independent groups of B*57-positive mice (M31 and M51; 9-12 mice per time point) exhibited significantly greater control of viral replication over the plateau stage of weeks 6 through 12, with mean viral loads greater than 0.6 log₁₀ lower than in B*57-negative mice (42,000 versus 178,000 copies/ml; $p < 0.03$). These data support the association of some protective HLA alleles, such as HLA-B*57, with significantly stronger control of HIV-1 viremia is recapitulated in humanized BLT mice.

Discussion

The development of improved animal models capable of more accurately mimicking natural *in vivo* human immune responses to host pathogens would substantially accelerate biomedical research and facilitate the development of efficacious vaccines and therapeutics. Here we explored the nature of human cellular immune responses to HIV-1 and viral evolution in the humanized BLT mouse model. Our data reveal that the specificity,

functionality and kinetics of HIV-1 specific CD8⁺ T-cell responses and viral escape pathways in BLT mice appear to closely resemble those seen in natural HIV-1 infection in humans.

While cellular immune responses have been previously been shown to develop in humanized mice (7-10, 51, 52) there has been a paucity of data regarding the specificity of these responses at the epitope level. This, along with the limited data on the functionality and effectiveness of these responses against a human pathogen, has restricted our knowledge regarding the extent to which immune responses in these models accurately reflect those seen in humans. We were able to detect HIV-1 specific cellular immune responses in humanized BLT mice both through stimulation of epitope-specific T-cell lines and directly *ex vivo*. The ability to detect responses at the epitope-specific level, combined with the viral escape data discussed below, indicates that this humanized BLT mouse model may be an attractive model to study the role of human epitope-specific responses to numerous pathogens as well as the factors governing the early induction and immunodominance patterns of CD8⁺ T-cell responses.

A particular strength of the humanized mouse model is its ability to generate multiple genetically identical animals. Due to the extensive genetic diversity within the human population the study of immune responses and clinical outcomes in individuals expressing similar host genetics has proven critical to our understanding of the factors governing host immunity. Two studies of identical twins infected at the same time with the same source of HIV-1 have demonstrated that the kinetics and specificity of cellular immune responses to HIV-1 can be highly reproducible (3, 53). Similar observations have been made in Mauritian macaques that exhibit low levels of MHC-I diversity (54). These studies reveal that there exist highly predictable patterns of CD8⁺ T-cell immunodominance during the acute phase of infection (50, 55, 56), which ultimately results in very similar patterns of viral escape from these responses (3, 57). These data, while limited to only a few unique studies, have been critical to our understanding of the extent to which the specificity of early, dominant CD8⁺ T-cell responses are dictated by both host and viral factors. Thus, the reproducibility of cellular immune responses and viral escape patterns seen among BLT mice with genetically identical immune systems suggests that this model has the potential to enable a more reliable interpretation of factors driving the specificity of early CD8⁺ T-cell responses and immunodominance patterns. Such knowledge may be critical to the design of vaccine antigens that would be capable of overcoming these natural immunodominance patterns in order to elicit responses that may more critical to the control of HIV-1 (58, 59).

Characterization of early genome-wide viral sequence evolution in BLT mice revealed that mutations were specific to well-defined CD8 epitopes and were reproducible across mice expressing the same restricting HLA-allele. These data are consistent with studies in HIV-1 and SIV illustrating that the cellular immune response represents the major driving force of early viral sequence evolution (20, 46, 60). Importantly, the Env A*01-RY9 and Nef C*03-AL9 epitopes that rapidly evolved in M20 mice represent the most immunodominant acute phase responses for each of these alleles in humans (55). Rapid viral escape was also observed in the B*57-restricted Rev-KY10 and Nef-KF9 epitopes, both of which have been shown to quickly escape in humans prior to the commonly targeted B*57-KF11, -IW9 and -TW10 epitopes in Gag (46). These data not only suggest that humanized BLT mice can effectively mount multiple epitope-specific CD8⁺ T-cell responses very early after infection, but that early CD8 epitope-specificity, an attribute critical to the control of HIV-1 (43, 55), may also be accurately reproduced in these mice. Furthermore, the escape pathways and kinetics observed in the escaping CD8 epitopes also resembled those seen in humans (18, 46). Even the Env A*02-LL9 epitope, where slower viral escape was observed only subsequent to escape in the other two Env and Nef epitopes, appears to be rarely targeted in

humans and likely represents a subdominant CD8 epitope (22, 23). This pattern of evolution is similar to the normal shift in selection pressures towards secondary targets following viral escape from immunodominant epitopes during natural infection. Therefore, our data illustrates that the relative selection pressures upon HIV-1 appear similar to those observed in acutely infected humans.

The mechanism associated with the ability of some HLA alleles to control HIV-1 infection appears to be due, at least in part, to the specificity of the CD8⁺ T-cell responses and their ability to dominate the early T-cell repertoire. In general Gag-specific CD8⁺ T-cell responses are broadly associated with the control of HIV-1 (39), and each of the protective HLA alleles -B*57, -B*27, and -B*13 restrict dominant CD8⁺ T-cell responses against highly conserved regions of HIV-1 Gag (24, 61, 62). In humanized BLT mice expressing HLA-B*57 we were able to detect acute phase responses to the three commonly targeted B*57-restricted epitopes TW10, IW9 and KF11 in Gag at magnitudes that are in line with those observed in a cohort of HLA-B*57 positive humans (43). In humans, the targeting of conserved regions of the virus such as Gag results in either delayed escape from these responses or the eventual selection of deleterious escape mutations that impair viral replication (25, 27, 36, 63), translating into lower plasma viral loads and delayed disease progression (64-66). Similarly, in mice expressing HLA-B*57 we did not observe rapid development of escape mutations within the B*57-restricted Gag epitopes, and these mice exhibited a greater than 0.6 log₁₀ lower level of viremia. This level of viral control in humans is associated with a significant reduction in risk for progression to AIDS or death (67-69), and is also in line with the 0.7 log₁₀ difference in viral set point associated with the expression of HLA-B*57 observed in a large cohort of chronically infected individuals (70).

While our data support use of the humanized BLT mouse model to complement studies in the SIV-infected rhesus macaque model, the small blood volumes available from these mice may limit more comprehensive immunological studies unless additional mice can be sacrificed. In addition, *ex vivo* PBMCs and even splenocytes from these animals responded suboptimally to stimulation with peptide antigen or even PMA/ionomycin, which we reason may be due to poor antigen presentation or the lack of sufficient co-stimulatory signals. In light of this apparent defect we reemphasize that our data indicate that the immune system still provides sufficient pressure on the virus to drive the evolution of CTL escape mutations with similar kinetics as seen in humans. Similarly, while we saw no correlation between the level of reconstitution of any measured cell type with viral loads nor the rate of viral escape between mice, it is possible that subtle differences in reconstitution levels at the time of challenge could affect individual response rates. In addition, in our study mice were infected with a high dose of HIV-1 via the intraperitoneal route to guarantee infection of all mice. Future efforts will be required to determine the optimal dose of HIV-1 required to establish efficient levels of infection by both mucosal routes, as well as through multiple low-dose exposures that have recently proven critical for gauging vaccine efficacy in the SIV infected macaque model. Finally, while this study was focused on HIV-1 specific CD8⁺ T-cell responses, it will be of great interest for future studies to determine the extent to which other arms of the immune system, including CD4⁺ T-cell responses, neutralizing antibodies, and natural killer cell responses recapitulate those of natural HIV-1 infection.

The ability of the humanized BLT mouse model to generate groups of genetically identical animals could greatly facilitate identification of the host and viral factors associated with the induction of human immune responses as well as mechanisms of immune control of HIV-1. The ability to vary a single experimental component (e.g. viral strain, vaccine antigen or adjuvant), adoptively transfer T-cells, and deplete immune subsets, all while examining the same HIV-1-specific responses observed in subjects would enable the more precise identification of immune correlates of control of HIV-1 in humans. Furthermore, the

availability of genetically identical animals should provide additional power for vaccine studies due to removal of the heterogeneous host genetic component that can often confound vaccine studies. In particular, this model may lend itself well to the study of CD8⁺ T cell immunodominance whereby manipulation of immunogens to focus responses towards CD8 epitopes that are relatively constrained in their ability to evolve escape mutations is believed to be critical to the control of HIV-1. Such studies could facilitate the design of vaccine approaches that induce more robust, longer-lived immune responses that provide better protection (58).

In summary, we have shown that humanized BLT mice are capable of rapidly mounting HIV-1-specific CD8⁺ T-cell responses that reflect the epitope specificity and kinetics observed during HIV-1 infection of humans. Moreover, the relative ease by which HIV-1 escapes some but not all CD8⁺ T-cell responses in BLT mice also appears to be conserved. Finally, the expression of the protective HLA-B*57 allele in BLT mice enabled the mounting of responses against conserved regions of HIV-1 Gag that are associated with greater control of viral replication in humans and our data now indicate this association is conserved in these mice. Taken together, these results suggest that the humanized BLT mouse model represents a fundamental advancement in the ability of small animal models to accurately reproduce human-specific immune responses to human pathogens, and supports the ability of this model to complement pathogenesis and vaccine studies for HIV-1, as well as a number of other human pathogens.

Materials and Methods

Animals and Infections

NOD/SCID and NOD/SCID/IL2R $\gamma^{-/-}$ mice (The Jackson Laboratory) were housed in a pathogen-free facility at Massachusetts General Hospital, were maintained in microisolator cages, fed autoclaved food and water and were reconstituted with human tissue as described (8). Mice were generally considered reconstituted if greater than 40% of cells in the lymphocyte gate were human CD45⁺ and greater than 30% of these human CD45⁺ lymphocytes were human CD3⁺. We performed genotyping of the *HLA* locus using PCR-SSOP (sequence-specific oligonucleotide probing) and PCR-SBT (sequence based typing). Viral stocks of the JR-CSF HIV-1 molecular clone were produced through transfection of HEK293T cells and titered as described (63). Mice were infected with 1×10^5 TCID₅₀ via the intraperitoneal route. Every two weeks p.i. approximately 200ul of blood was obtained through puncture of the retro-orbital sinus or submandibular vein for isolation of plasma virus.

RNA isolations and viral load quantitation

Viral RNA was isolated using the QiaAmp Viral RNA Mini Kit (Qiagen). Plasma viral loads were determined by quantitative RT-PCR using the QuantiFast Syber Green RT-PCR kit (Qiagen) as described (63).

Viral sequencing

Plasma viral RNA was subjected to RT-PCR using the SuperScript III One-Step RT-PCR System (Invitrogen). PCR products were amplified using nested PCR with two overlapping sets of primers covering the entire HIV-1 proteome. Products were ligated into pCR2.1 (Invitrogen) and individual clones were sequenced using the ABI Prism 3100 Genetic Analyzer (Applied Biosystems). Highlighter plots were produced using tools from the HIV Molecular Database at the Los Alamos National Laboratory (<http://www.hiv.lanl.gov>).

Generation of HIV-specific T-cell lines and B-cell lines

Epitope specific T-cell lines were produced by pulsing 2 million splenocytes with specific peptides (12 µg/ml) in the presence of 10M irradiated allogenic PBMCs and grown in RPMI with 10% FCS and 50 U/ml IL-2 (71). B-cell lines (BCL) were produced from PBMCs via infection with EBV from the supernatant of the B95-8 cell line (ATCC: CRL-1612) in the presence of cyclosporine A (72).

Measurement of CD8⁺ T-cell responses by IFN-γ ELISpot assay

T-cell lines were tested for activity using an IFN-γ ELISpot assay (44). For direct *ex vivo* IFN-γ ELISpot assays isogenic BCL at 2 million cells/ml were pulsed with peptide at a final concentration of 100µg/ml and incubated at 37°C, 5% CO₂ in a humidified incubator for 1 hr prior to assay. Then 200,000 peptide pulsed BCL were added to 100,000 cells in 200µl on a 96-well Immobilon-P filter plate (Millipore) and incubated at 37°C for 48hrs before colorimetric development. Negative controls for ELISpot assays were incubated with a non-specific influenza peptide, influenza peptide-pulsed isogenic BCL or HLA mismatched allogenic BCL pulsed with HIV-1 peptide.

Intracellular Cytokine Staining (ICS) and MHC-I tetramer staining

IFN-γ production from T-cell lines was measured through flow cytometry. We stimulated 1×10^6 T-cells with the corresponding specific peptides Env A*01-RY9 or Nef C*03-AL9 (20µg/ml). Negative controls were stimulated with an influenza peptide. The splenocytes were incubated with peptide for 1 hr, Brefeldin A was added and cells were incubated for 4 more hrs. Cells were stained with antibodies against human CD3, CD4 and CD8 for 20 min. then fixed with Perm A and permeabilized with Perm B (BD Biosciences) and stained with antibodies against IFN-γ for 20 min. Samples were analyzed via flow cytometry. For MHC-I tetramer staining, of both the T-cell line and the mix of cells from the spleen and thymic organoid from a mouse, cells were stained with antibodies against CD8 and antigen specific MHC-I tetramers for 30 min. Here, spleen and thymic organoid were pooled to increase the number of cells obtained from the mouse. Cells were washed and fixed in 1% paraformaldehyde and analyzed via flow cytometry.

Statistical Analysis

Mann-Whitney-Wilcoxon was used to determine significant differences between viral loads. Fisher's Exact test was used to determine if the number of non-synonymous mutations arising within well-defined CD8⁺ CTL epitopes restricted by the M20 mice (21) was significantly higher than the total number of mutations found outside these confirmed epitopes. An unpaired Student's t-test was used to compare ELISpot results between wild-type and mutant peptides.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Drs. Mary Carrington and Hendrik Streeck for providing information regarding HLA-B*57-specific immune responses and control.

Funding: This study was supported by National Institutes of Health grants R01AI090698, P01AI07889, P30AI060354 and P01AI078897, a Platform Award from the Ragon Institute of MGH, MIT and Harvard, the Harvard University Center for AIDS Research grant P30AI060354 and with federal funds from the National Cancer Institute under Contract No. HHSN261200800001E and by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. The content of this publication does not necessarily reflect the views

or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

References

1. Koff WC, Johnson PR, Watkins DI, Burton DR, Lifson JD, Hasenkrug KJ, McDermott AB, Schultz A, Zamb TJ, Boyle R, Desrosiers RC. HIV vaccine design: insights from live attenuated SIV vaccines. *Nat Immunol*. 2006; 7:19. published online EpubJan. 10.1038/ni1296 [PubMed: 16357854]
2. Liu J, O'Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM, Abbink P, Coffey RT, Grandpre LE, Seaman MS, Landucci G, Forthal DN, Montefiori DC, Carville A, Mansfield KG, Havenga MJ, Pau MG, Goudsmit J, Barouch DH. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. *Nature*. 2009; 457:87. published online EpubJan 1. 10.1038/nature07469 [PubMed: 18997770]
3. Draenert R, Allen TM, Liu Y, Wrin T, Chappey C, Verrill CL, Sirera G, Eldridge RL, Lahaie MP, Ruiz L, Clotet B, Petropoulos CJ, Walker BD, Martinez-Picado J. Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus. *J Exp Med*. 2006; 203:529. published online EpubMar 20. 10.1084/jem.20052116 [PubMed: 16533886]
4. Wiseman RW, Wojcechowskyj JA, Greene JM, Blasky AJ, Gopon T, Soma T, Friedrich TC, O'Connor SL, O'Connor DH. Simian immunodeficiency virus SIVmac239 infection of major histocompatibility complex-identical cynomolgus macaques from Mauritius. *J Virol*. 2007; 81:349. published online EpubJan. 10.1128/JVI.01841-06 [PubMed: 17035320]
5. Boberg A, Brave A, Johansson S, Wahren B, Hinkula J, Rollman E. Murine models for HIV vaccination and challenge. *Expert Rev Vaccines*. 2008; 7:117. published online EpubFeb. 10.1586/14760584.7.1.117 [PubMed: 18251698]
6. Shacklett BL. Mucosal immunity to HIV: a review of recent literature. *Curr Opin HIV AIDS*. 2008; 3:541. published online EpubSep. 10.1097/COH.0b013e32830ab9ee [PubMed: 19373019]
7. Melkus MW, Estes JD, Padgett-Thomas A, Gatlin J, Denton PW, Othieno FA, Wege AK, Haase AT, Garcia JV. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. *Nat Med*. 2006; 12:1316. published online EpubNov. 10.1038/nm1431 [PubMed: 17057712]
8. Brainard DM, Seung E, Frahm N, Cariappa A, Bailey CC, Hart WK, Shin HS, Brooks SF, Knight HL, Eichbaum Q, Yang YG, Sykes M, Walker BD, Freeman GJ, Pillai S, Westmoreland SV, Brander C, Luster AD, Tager AM. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. *J Virol*. 2009; 83:7305. published online EpubJul. 10.1128/JVI.02207-08 [PubMed: 19420076]
9. Rajesh D, Zhou Y, Jankowska-Gan E, Roenneburg DA, Dart ML, Torrealba J, Burlingham WJ. Th1 and Th17 immunocompetence in humanized NOD/SCID/IL2rgammanull mice. *Hum Immunol*. 2010; 71:551. published online EpubJun. 10.1016/j.humimm.2010.02.019 [PubMed: 20298731]
10. Traggiai E, Chicha L, Mazzucchelli L, Bronz L, Piffaretti JC, Lanzavecchia A, Manz MG. Development of a human adaptive immune system in cord blood cell-transplanted mice. *Science*. 2004; 304:104. published online EpubApr 2. 10.1126/science.1093933 [PubMed: 15064419]
11. Gorantla S, Makarov E, Finke-Dwyer J, Gebhart CL, Domm W, Dewhurst S, Gendelman HE, Poluektova LY. CD8+ cell depletion accelerates HIV-1 immunopathology in humanized mice. *J Immunol*. 2010; 184:7082. published online EpubJun 15. 10.4049/jimmunol.1000438 [PubMed: 20495069]
12. Kwant-Mitchell A, Ashkar AA, Rosenthal KL. Mucosal innate and adaptive immune responses against herpes simplex virus type 2 in a humanized mouse model. *J Virol*. 2009; 83:10664. published online EpubOct. 10.1128/JVI.02584-08 [PubMed: 19656896]
13. Baenziger S, Tussiwand R, Schlaepfer E, Mazzucchelli L, Heikenwalder M, Kurrer MO, Behnke S, Frey J, Oxenius A, Joller H, Aguzzi A, Manz MG, Speck RF. Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-gamma c-/- mice. *Proc Natl Acad Sci U S A*. 2006; 103:15951. published online EpubOct 24. 10.1073/pnas.0604493103 [PubMed: 17038503]

14. Sun Z, Denton PW, Estes JD, Othieno FA, Wei BL, Wege AK, Melkus MW, Padgett-Thomas A, Zupancic M, Haase AT, Garcia JV. Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. *J Exp Med*. 2007; 204:705. published online EpubApr 16. 10.1084/jem.20062411 [PubMed: 17389241]
15. An DS, Poon B, Ho Tsong Fang R, Weijer K, Blom B, Spits H, Chen IS, Uittenbogaart CH. Use of a novel chimeric mouse model with a functionally active human immune system to study human immunodeficiency virus type 1 infection. *Clin Vaccine Immunol*. 2007; 14:391. published online EpubApr. 10.1128/CVI.00403-06 [PubMed: 17314230]
16. Stoddart CA, Maidji E, Galkina SA, Kosikova G, Rivera JM, Moreno ME, Sloan B, Joshi P, Long BR. Superior human leukocyte reconstitution and susceptibility to vaginal HIV transmission in humanized NOD-scid IL-2Rgamma(-/-) (NSG) BLT mice. *Virology*. 2011 published online EpubJun 17. 10.1016/j.virol.2011.05.013
17. Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. *Science*. 2002; 296:1439. published online EpubMay 24. 10.1126/science.1069660 [PubMed: 12029127]
18. Brumme ZL, John M, Carlson JM, Brumme CJ, Chan D, Brockman MA, Swenson LC, Tao I, Szeto S, Rosato P, Sela J, Kadie CM, Frahm N, Brander C, Haas DW, Riddler SA, Haubrich R, Walker BD, Harrigan PR, Heckerman D, Mallal S. HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. *PLoS One*. 2009; 4:e6687.10.1371/journal.pone.0006687 [PubMed: 19690614]
19. Rousseau CM, Daniels MG, Carlson JM, Kadie C, Crawford H, Prendergast A, Matthews P, Payne R, Rolland M, Raugi DN, Maust BS, Learn GH, Nickle DC, Coovadia H, Ndung'u T, Frahm N, Brander C, Walker BD, Goulder PJ, Bhattacharya T, Heckerman DE, Korber BT, Mullins JI. HLA class I-driven evolution of human immunodeficiency virus type 1 subtype c proteome: immune escape and viral load. *J Virol*. 2008; 82:6434. published online EpubJul. 10.1128/JVI.02455-07 [PubMed: 18434400]
20. Allen TM, Altfeld M, Geer SC, Kalife ET, Moore C, O'Sullivan M, Desouza KI, Feeney ME, Eldridge RL, Maier EL, Kaufmann DE, Lahaie MP, Reyor L, Tanzi G, Johnston MN, Brander C, Draenert R, Rockstroh JK, Jessen H, Rosenberg ES, Mallal SA, Walker BD. Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. *J Virol*. 2005; 79:13239. published online EpubNov. 10.1128/JVI.79.21.13239-13249.2005 [PubMed: 16227247]
21. Llano, A.; Frahm, N.; Brander, C. HIV Molecular Immunology 2009. Yusim, K.; Korber, BTM.; Brander, C.; Haynes, BF.; Koup, R.; Moore, JP.; Walker, BD.; Watkins, DI., editors. Los Alamos National Laboratory, Theoretical Biology and Biophysics; Los Alamos, New Mexico: 2009. p. 3-24.
22. Kundu SK, Dupuis M, Sette A, Celis E, Dorner F, Eibl M, Merigan TC. Role of preimmunization virus sequences in cellular immunity in HIV-infected patients during HIV type 1 MN recombinant gp160 immunization. *AIDS Res Hum Retroviruses*. 1998; 14:1669. [PubMed: 9870321]
23. Yusim, K.; Korber, Bette TM.; Brander, Christian; Haynes, Barton F.; Koup, Richard; Moore, John P.; Walker, Bruce D.; Watkins, David I., editors. HIV Molecular Immunology 2009. Los Alamos National Laboratory, Theoretical Biology and Biophysics; Los Alamos: 2009.
24. Schneidewind A, Brockman MA, Sidney J, Wang YE, Chen H, Suscovich TJ, Li B, Adam RI, Allgaier RL, Mothe BR, Kuntzen T, Oniangue-Ndza C, Trocha A, Yu XG, Brander C, Sette A, Walker BD, Allen TM. Structural and functional constraints limit options for cytotoxic T-lymphocyte escape in the immunodominant HLA-B27-restricted epitope in human immunodeficiency virus type 1 capsid. *J Virol*. 2008; 82:5594. published online EpubJun. 10.1128/JVI.02356-07 [PubMed: 18385228]
25. Schneidewind A, Brockman MA, Yang R, Adam RI, Li B, Le Gall S, Rinaldo CR, Craggs SL, Allgaier RL, Power KA, Kuntzen T, Tung CS, LaBute MX, Mueller SM, Harter T, McMichael AJ, Goulder PJ, Aiken C, Brander C, Kelleher AD, Allen TM. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. *J Virol*. 2007; 81:12382. published online EpubNov. 10.1128/JVI.01543-07 [PubMed: 17804494]

26. Dahirel V, Shekhar K, Pereyra F, Miura T, Artyomov M, Talsania S, Allen TM, Altfeld M, Carrington M, Irvine DJ, Walker BD, Chakraborty AK. From the Cover: Coordinate linkage of HIV evolution reveals regions of immunological vulnerability. *Proc Natl Acad Sci U S A*. 2011; 108:11530. published online EpubJul 12. 10.1073/pnas.1105315108 [PubMed: 21690407]
27. Martinez-Picado J, Prado JG, Fry EE, Pfafferoth K, Leslie A, Chetty S, Thobakgale C, Honeyborne I, Crawford H, Matthews P, Pillay T, Rousseau C, Mullins JI, Brander C, Walker BD, Stuart DI, Kiepiela P, Goulder P. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. *J Virol*. 2006; 80:3617. published online EpubApr. 10.1128/JVI.80.7.3617-3623.2006 [PubMed: 16537629]
28. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, Wei X, Jiang C, Kirchherr JL, Gao F, Anderson JA, Ping LH, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Cohen MS, Montefiori DC, Haynes BF, Gaschen B, Athreya GS, Lee HY, Wood N, Seoighe C, Perelson AS, Bhattacharya T, Korber BT, Hahn BH, Shaw GM. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. *Proc Natl Acad Sci U S A*. 2008; 105:7552. published online EpubMay 27. 10.1073/pnas.0802203105 [PubMed: 18490657]
29. Fischer W, Ganusov VV, Giorgi EE, Hraber PT, Keele BF, Leitner T, Han CS, Gleasner CD, Green L, Lo CC, Nag A, Wallstrom TC, Wang S, McMichael AJ, Haynes BF, Hahn BH, Perelson AS, Borrow P, Shaw GM, Bhattacharya T, Korber BT. Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. *PLoS One*. 2010; 5:e12303. 10.1371/journal.pone.0012303 [PubMed: 20808830]
30. Preston BD, Poesz BJ, Loeb LA. Fidelity of HIV-1 reverse transcriptase. *Science*. 1988; 242:1168. [PubMed: 2460924]
31. Bebenek K, Abbotts J, Roberts JD, Wilson SH, Kunkel TA. Specificity and mechanism of error-prone replication by human immunodeficiency virus-1 reverse transcriptase. *J Biol Chem*. 1989; 264:16948. [PubMed: 2476448]
32. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. *Nature*. 2003; 424:99. published online EpubJul 3. 10.1038/nature01709 [PubMed: 12808466]
33. Beale RC, Petersen-Mahrt SK, Watt IN, Harris RS, Rada C, Neuberger MS. Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. *J Mol Biol*. 2004; 337:585. published online EpubMar 26. 10.1016/j.jmb.2004.01.046 [PubMed: 15019779]
34. Jern P, Russell RA, Pathak VK, Coffin JM. Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. *PLoS Pathog*. 2009; 5:e1000367. published online EpubApr. 10.1371/journal.ppat.1000367
35. Sato K, Izumi T, Misawa N, Kobayashi T, Yamashita Y, Ohmichi M, Ito M, Takaori-Kondo A, Koyanagi Y. Remarkable lethal G-to-A mutations in vif-proficient HIV-1 provirus by individual APOBEC3 proteins in humanized mice. *J Virol*. 2010; 84:9546. published online EpubSep. 10.1128/JVI.00823-10 [PubMed: 20610708]
36. Brockman MA, Schneidewind A, Lahaie M, Schmidt A, Miura T, Desouza I, Ryvkin F, Derdeyn CA, Allen S, Hunter E, Mulenga J, Goepfert PA, Walker BD, Allen TM. Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. *J Virol*. 2007; 81:12608. published online EpubNov. 10.1128/JVI.01369-07 [PubMed: 17728232]
37. Klein MR, van der Burg SH, Hovenkamp E, Holwerda AM, Drijfhout JW, Melief CJ, Miedema F. Characterization of HLA-B57-restricted human immunodeficiency virus type 1 Gag- and RT-specific cytotoxic T lymphocyte responses. *J Gen Virol*. 1998; 79(Pt 9):2191. [PubMed: 9747728]
38. Goulder PJ, Bunce M, Krausa P, McIntyre K, Crowley S, Morgan B, Edwards A, Giangrande P, Phillips RE, McMichael AJ. Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection. *AIDS Res Hum Retroviruses*. 1996; 12:1691. [PubMed: 8959245]
39. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, Reddy S, de Pierres C, Mncube Z, Mkhwanazi N, Bishop K, van der Stok M, Nair K, Khan N, Crawford H,

- Payne R, Leslie A, Prado J, Prendergast A, Frater J, McCarthy N, Brander C, Learn GH, Nickle D, Rousseau C, Coovadia H, Mullins JI, Heckerman D, Walker BD, Goulder P. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. *Nat Med.* 2007; 13:46. [PubMed: 17173051]
40. Beverly B, Kang SM, Lenardo MJ, Schwartz RH. Reversal of in vitro T cell clonal anergy by IL-2 stimulation. *Int Immunol.* 1992; 4:661. [PubMed: 1616898]
 41. Sidhu S, Deacock S, Bal V, Batchelor JR, Lombardi G, Lechler RI. Human T cells cannot act as autonomous antigen-presenting cells, but induce tolerance in antigen-specific and alloreactive responder cells. *J Exp Med.* 1992; 176:875. [PubMed: 1512550]
 42. Jarman ER, Perschke K, Montermann E, Herz U, Renz H, Knop J, Reske-Kunz AB. Deficient cytokine response of human allergen-specific T lymphocytes from humanized SCID mice and reconstitution by professional antigen-presenting cells. *J Allergy Clin Immunol.* 2000; 105:967. published online EpubMay. 10.1067/mai.2000.105320 [PubMed: 10808178]
 43. Altfeld M, Kalife ET, Qi Y, Streeck H, Lichterfeld M, Johnston MN, Burgett N, Swartz ME, Yang A, Alter G, Yu XG, Meier A, Rockstroh JK, Allen TM, Jessen H, Rosenberg ES, Carrington M, Walker BD. HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1. *PLoS Med.* 2006; 3:e403. published online EpubOct. 10.1371/journal.pmed.0030403 [PubMed: 17076553]
 44. Frahm N, Korber BT, Adams CM, Szinger JJ, Draenert R, Addo MM, Feeney ME, Yusim K, Sango K, Brown NV, SenGupta D, Piechocka-Trocha A, Simonis T, Marincola FM, Wurcel AG, Stone DR, Russell CJ, Adolf P, Cohen D, Roach T, StJohn A, Khatri A, Davis K, Mullins J, Goulder PJ, Walker BD, Brander C. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. *J Virol.* 2004; 78:2187. [PubMed: 14963115]
 45. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, Chetty S, Rathnavalu P, Moore C, Pfafferoth KJ, Hilton L, Zimbwa P, Moore S, Allen T, Brander C, Addo MM, Altfeld M, James I, Mallal S, Bunce M, Barber LD, Szinger J, Day C, Klennerman P, Mullins J, Korber B, Coovadia HM, Walker BD, Goulder PJ. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. *Nature.* 2004; 432:769. published online EpubDec 9. 10.1038/nature03113 [PubMed: 15592417]
 46. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, Ferrari G, Giorgi E, Gnanou VV, Keele BF, Learn GH, Turnbull EL, Salazar MG, Weinhold KJ, Moore S, Letvin N, Haynes BF, Cohen MS, Hraber P, Bhattacharya T, Borrow P, Perelson AS, Hahn BH, Shaw GM, Korber BT, McMichael AJ. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. *J Exp Med.* 2009; 206:1253. published online EpubJun 8. 10.1084/jem.20090365 [PubMed: 19487423]
 47. Allen TM, Altfeld M, Yu XG, O'Sullivan KM, Lichterfeld M, Le Gall S, John M, Mothe BR, Lee PK, Kalife ET, Cohen DE, Freedberg KA, Strick DA, Johnston MN, Sette A, Rosenberg ES, Mallal SA, Goulder PJ, Brander C, Walker BD. Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. *J Virol.* 2004; 78:7069. published online EpubJul. 10.1128/JVI.78.13.7069-7078.2004 [PubMed: 15194783]
 48. Crawford H, Lumm W, Leslie A, Schaefer M, Boeras D, Prado JG, Tang J, Farmer P, Ndung'u T, Lakhi S, Gilmour J, Goepfert P, Walker BD, Kaslow R, Mulenga J, Allen S, Goulder PJ, Hunter E. Evolution of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703-positive individuals and their transmission recipients. *J Exp Med.* 2009; 206:909. published online EpubApr 13. 10.1084/jem.20081984 [PubMed: 19307327]
 49. Trivedi HN, HayGlass KT, Gangur V, Allardice JG, Embree JE, Plummer FA. Analysis of neonatal T cell and antigen presenting cell functions. *Hum Immunol.* 1997; 57:69. published online EpubOct. [PubMed: 9438198]
 50. Streeck H, Lichterfeld M, Alter G, Meier A, Teigen N, Yassine-Diab B, Sidhu HK, Little S, Kelleher A, Routy JP, Rosenberg ES, Sekaly RP, Walker BD, Altfeld M. Recognition of a defined region within p24 gag by CD8+ T cells during primary human immunodeficiency virus type 1 infection in individuals expressing protective HLA class I alleles. *J Virol.* 2007; 81:7725. published online EpubJul. 10.1128/JVI.00708-07 [PubMed: 17494064]

51. Lan P, Tonomura N, Shimizu A, Wang S, Yang YG. Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation. *Blood*. 2006; 108:487. published online EpubJul 15. 10.1182/blood-2005-11-4388 [PubMed: 16410443]
52. Issa F, Hester J, Goto R, Nadig SN, Goodacre TE, Wood K. Ex vivo-expanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model. *Transplantation*. 2010; 90:1321. published online EpubDec 27. 10.1097/TP.0b013e3181ff8772 [PubMed: 21048528]
53. Yang OO, Church J, Kitchen CM, Kilpatrick R, Ali A, Geng Y, Killian MS, Sabado RL, Ng H, Suen J, Bryson Y, Jamieson BD, Krogstad P. Genetic and stochastic influences on the interaction of human immunodeficiency virus type 1 and cytotoxic T lymphocytes in identical twins. *J Virol*. 2005; 79:15368. published online EpubDec. 10.1128/JVI.79.24.15368-15375.2005 [PubMed: 16306608]
54. Greene JM, Burwitz BJ, Blasky AJ, Mattila TL, Hong JJ, Rakasz EG, Wiseman RW, Hasenkrug KJ, Skinner PJ, O'Connor SL, O'Connor DH. Allogeneic lymphocytes persist and traffic in feral MHC-matched mauritian cynomolgus macaques. *PLoS One*. 2008; 3:e2384.10.1371/journal.pone.0002384 [PubMed: 18545705]
55. Streeck H, John JS, Qi Y, Yassine-Diab B, Johnson RC, Kwon DS, Addo MM, Brumme C, Routy JP, Little S, Jessen HK, Kelleher AD, Hecht FM, Sekaly RP, Rosenberg ES, Walker BD, Carrington M, Altfeld M. Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. *J Virol*. 2009; 83:7641. published online EpubAug. 10.1128/JVI.00182-09 [PubMed: 19458000]
56. Lichterfeld M, Yu XG, Le Gall S, Altfeld M. Immunodominance of HIV-1-specific CD8(+) T-cell responses in acute HIV-1 infection: at the crossroads of viral and host genetics. *Trends Immunol*. 2005; 26:166. published online EpubMar. 10.1016/j.it.2005.01.003 [PubMed: 15745859]
57. Wang YE, Li B, Carlson JM, Streeck H, Gladden AD, Goodman R, Schneidewind A, Power KA, Toth I, Frahm N, Alter G, Brander C, Carrington M, Walker BD, Altfeld M, Heckerman D, Allen TM. Protective HLA class I alleles that restrict acute-phase CD8+ T-cell responses are associated with viral escape mutations located in highly conserved regions of human immunodeficiency virus type 1. *J Virol*. 2009; 83:1845. published online EpubFeb. 10.1128/JVI.01061-08 [PubMed: 19036810]
58. Boutwell CL, Rolland MM, Herbeck JT, Mullins JJ, Allen TM. Viral evolution and escape during acute HIV-1 infection. *J Infect Dis*. 2010; 202(Suppl 2):S309. published online EpubOct 15. 10.1086/655653 [PubMed: 20846038]
59. Altfeld M, Allen TM. Hitting HIV where it hurts: an alternative approach to HIV vaccine design. *Trends Immunol*. 2006; 27:504. published online EpubNov. 10.1016/j.it.2006.09.007 [PubMed: 16997629]
60. O'Connor DH, Allen TM, Vogel TU, Jing P, DeSouza IP, Dodds E, Dunphy EJ, Melsaether C, Mothe B, Yamamoto H, Horton H, Wilson N, Hughes AL, Watkins DI. Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. *Nat Med*. 2002; 8:493. published online EpubMay. 10.1038/nm0502-493 [PubMed: 11984594]
61. Rolland M, Heckerman D, Deng W, Rousseau CM, Coovadia H, Bishop K, Goulder PJ, Walker BD, Brander C, Mullins JJ. Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. *PLoS One*. 2008; 3:e1424.10.1371/journal.pone.0001424
62. Borghans JA, Molgaard A, de Boer RJ, Kesmir C. HLA alleles associated with slow progression to AIDS truly prefer to present HIV-1 p24. *PLoS One*. 2007; 2:e920.10.1371/journal.pone.0000920 [PubMed: 17878955]
63. Boutwell CL, Rowley CF, Essex M. Reduced viral replication capacity of human immunodeficiency virus type 1 subtype C caused by cytotoxic-T-lymphocyte escape mutations in HLA-B57 epitopes of capsid protein. *J Virol*. 2009; 83:2460. published online EpubMar. 10.1128/JVI.01970-08 [PubMed: 19109381]
64. Kaslow RA, Carrington M, Apple R, Park L, Munoz A, Saah AJ, Goedert JJ, Winkler C, O'Brien SJ, Rinaldo C, Detels R, Blattner W, Phair J, Erlich H, Mann DL. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. *Nat Med*. 1996; 2:405. [PubMed: 8597949]

65. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, Hallahan CW, Selig SM, Schwartz D, Sullivan J, Connors M. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. *Proc Natl Acad Sci U S A*. 2000; 97:2709. published online EpubMar 14. 10.1073/pnas.050567397 [PubMed: 10694578]
66. Flores-Villanueva PO, Yunis EJ, Delgado JC, Vittinghoff E, Buchbinder S, Leung JY, Ugialoro AM, Clavijo OP, Rosenberg ES, Kalams SA, Braun JD, Boswell SL, Walker BD, Goldfeld AE. Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. *Proc Natl Acad Sci U S A*. 2001; 98:5140. published online EpubApr 24. 10.1073/pnas.071548198 [PubMed: 11309482]
67. Modjarrad K, Chamot E, Vermund SH. Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. *AIDS*. 2008; 22:2179. 00002030-200810180-00015. published online EpubOct 18. 10.1097/QAD.0b013e328312c756 [PubMed: 18832881]
68. Coombs RW, Welles SL, Hooper C, Reichelderfer PS, D'Aquila RT, Japour AJ, Johnson VA, Kuritzkes DR, Richman DD, Kwok S, Todd J, Jackson JB, DeGruttola V, Crumacker CS, Kahn J. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. *J Infect Dis*. 1996; 174:704. [PubMed: 8843206]
69. Welles SL, Jackson JB, Yen-Lieberman B, Demeter L, Japour AJ, Smeaton LM, Johnson VA, Kuritzkes DR, D'Aquila RT, Reichelderfer PA, Richman DD, Reichman R, Fischl M, Dolin R, Coombs RW, Kahn JO, McLaren C, Todd J, Kwok S, Crumacker CS. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team. *J Infect Dis*. 1996; 174:696. [PubMed: 8843205]
70. Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, Cirulli ET, Urban TJ, Zhang K, Gumbs CE, Smith JP, Castagna A, Cozzi-Lepri A, De Luca A, Easterbrook P, Gunthard HF, Mallal S, Mussini C, Dalmau J, Martinez-Picado J, Miro JM, Obel N, Wolinsky SM, Martinson JJ, Detels R, Margolick JB, Jacobson LP, Descombes P, Antonarakis SE, Beckmann JS, O'Brien SJ, Letvin NL, McMichael AJ, Haynes BF, Carrington M, Feng S, Telenti A, Goldstein DB. Common genetic variation and the control of HIV-1 in humans. *PLoS Genet*. 2009; 5:e1000791. published online EpubDec. 10.1371/journal.pgen.1000791
71. Walker BD, Flexner C, Birch-Limberger K, Fisher L, Paradis TJ, Aldovini A, Young R, Moss B, Schooley RT. Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. *Proc Natl Acad Sci USA*. 1989; 86:9514.
72. Caputo JL, Johnson A, McClintock P, Reid YA, Hay RJ. An effective method for establishing Human B lymphoblastic cell lines using Epstein-Barr Virus. *Methods in Cell Science*. 1991; 13:39.

Figure 1.

Evolution of Env and Nef reveals mutations predominantly confined to CD8 epitopes. HIV-1 was cloned and sequenced from (A) six M20 mice, and (B) three mice from three additional reconstitution groups (M16, M24, and M33) sharing one or more HLA alleles with M20. Individual viral clones spanning a 908bp fragment of Env and Nef were sequenced from each mouse indicated on the right. The Env and Nef open reading frames are shown as a single open reading frame. Each horizontal line represents a single clone. Each vertical colored dash represents evolution away from the infecting JR-CSF molecular clone, with non-synonymous mutations in red and synonymous mutations in green (<http://www.hiv.lanl.gov>). Grey boxes define the location of the Env A*01-RY9, Env A*02-LL9, and Nef C*03-AL9 epitopes only in mice expressing the respective HLA allele.

[illegible]

Figure 2. Reproducible patterns of sequence evolution were observed in restricted CD8 epitopes. For each mouse, and each time point, between 8-16 PCR clones spanning the three CD8 epitopes in Env and Nef were derived from a bulk sequencing reaction, cloned, and sequenced. The number of clones containing that sequence out of the total number of clones is indicated after the sequence. Amino acid substitutions are shown for the three targeted CD8 epitopes in each mouse at two time points, in weeks post-infection (w. PI), for (A) the six M20 mice and (B) a single mouse from three additional reconstitution groups. The sequence of each epitope is indicated at the top for both the 2004 subtype B consensus sequence (www.hiv.lanl.gov) and for the infecting JR-CSF strain. *Gray boxes* denote the location of the CD8 epitopes, *dashes* (-) denote amino acid residues matching JR-CSF.

Figure 3.

Detection of epitope specific CD8⁺ T-cell responses in BLT mice and the impact of CTL escape mutations. Env A*01-RY9 and Nef C*03-AL9 epitope specific T-cell lines were established from splenocytes harvested from mice M20-07 and M20-09 at 8 weeks p.i. (A) Antigen-specific IFN- γ expression by Env A*01-RY9 and Nef C*03-AL9 epitope specific T-cell lines as measured by ELISpot assay. (B) IFN- γ production from the Env A*01-RY9 T-cell line is derived from human CD3⁺ CD8⁺ T-cells as measured by intracellular cytokine staining (ICS). (C and D) Peptides encoding escape variants within the (C) Env A*01-RY9 and (D) Nef C*03-AL9 epitopes have reduced ability to stimulate IFN- γ expression from the respective T-cell lines. All experiments were done in triplicate. * indicates $p < 0.05$ for any mutant peptide against the wild-type by Unpaired t test with Welch's correction. Results in panels A, C and D are shown as mean $\pm$ SEM

Figure 4.

Direct *ex vivo* detection of epitope-specific CD8⁺ T-cell responses in HLA-B*57-positive BLT mice. (A) Antigen specific IFN- γ ELISpot responses were detected against five described B*57-restricted CD8 epitopes using PBMCs from M31 mice at week 10 post-infection. (B) IFN- γ ELISpot responses to these epitopes were detected in PBMCs from M51 mice at weeks 8, 10 and 12 post-infection. (C) MHC-I tetramer staining of human CD3⁺, CD8⁺ T-cells from a mixture of spleen and the liver/thymus organoid cells from an M51 mouse at week 12 post-infection. Included as a negative control is the HIV-1 B*08-FL8 peptide. Results are representative of the two mice tested, each tested in triplicate. Results in panels A and B are shown as mean $\pm$ SEM.

A	B*57 Gag-IW9													B*57 Gag-KF11													B*57 Gag-TW10																
	HQAISPRTLNWKV													IEEKAFSPSEVIPMFAL													AGTTSTLQEQIGWMTN																
	HQAISPRTLNWKV													IEEKAFSPSEVIPMFAL													AGTTSTLQEQIGWMTN																
2004 B cons																																											
JR-CSF																																											
M31-03	10 w. PI	-	-	-	-	-	-	-	-	-	-	-	-	15/15	-	-	-	-	-	-	-	-	-	-	-	15/15	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15/15	
M31-07	10 w. PI	-	-	-	-	-	-	-	-	-	-	-	-	15/16	-	-	-	-	-	-	-	-	-	-	-	16/16	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15/16	
		-	-	-	-	-	-	-	-	-	-	-	-	1/16	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1/16	
M31-09	10 w. PI	-	-	-	-	-	-	-	-	-	-	-	-	16/16	-	-	-	-	-	-	-	-	-	-	-	16/16	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	16/16
M31-12	10 w. PI	-	-	-	-	-	-	-	-	-	-	-	-	15/15	-	-	-	-	-	-	-	-	-	-	-	15/15	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15/15

B	B*57 Rev-KY10													B*57 Nef-KF9													Predicted B*57 Vpu-VW10															
	ELLKTVRLIKFLYQSN													MTYKGAIDLSHFLKE													ALVVGAGIIAIIVWSIV															
	DLLKTVRLIKFLYQSS													MTYKAAIDLSHFLKE													ALVVGAGIIAIIVWSIV					ALVVGAGIIAIIVWSIV										
M31-03	10 w. PI	-	-	-	-	-	-	-	-	-	-	-	-	7/17	-	-	-	-	-	-	-	-	-	-	9/12	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5/17
		-	-	-	-	-	-	-	-	-	-	-	-	5/17	-	-	-	-	-	-	-	-	-	3/13	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5/17
		-	-	-	-	-	-	-	-	-	-	-	-	4/17	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3/17	
		-	-	-	-	-	-	-	-	-	-	-	-	1/17	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3/17	
		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1/17		
M31-07	10 w. PI	-	-	-	-	-	-	-	-	-	-	-	-	9/12	-	-	-	-	-	-	-	-	-	12/12	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6/12
		-	-	-	-	-	-	-	-	-	-	-	-	3/12	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5/12		
		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1/12			
M31-09	10 w. PI	-	-	-	-	-	-	-	-	-	-	-	-	8/11	-	-	-	-	-	-	-	-	-	12/12	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4/10
		-	-	-	-	-	-	-	-	-	-	-	-	2/11	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4/10		
		-	-	-	-	-	-	-	-	-	-	-	-	1/11	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1/10		
		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1/10		
M31-12	10 w. PI	-	-	-	-	-	-	-	-	-	-	-	-	4/10	-	-	-	-	-	-	-	-	-	6/7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5/10	
		-	-	-	-	-	-	-	-	-	-	-	-	3/10	-	-	-	-	-	-	-	-	-	1/7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5/10	
		-	-	-	-	-	-	-	-	-	-	-	-	1/10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1/10	
		-	-	-	-	-	-	-	-	-	-	-	-	1/10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1/10	
		-	-	-	-	-	-	-	-	-	-	-	-	1/10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1/10	

Figure 5. Differential immune escape kinetics and reproducible mutation patterns within HLA-B*57-restricted CD8 epitopes in BLT mice. (A) Clonal sequences were derived from plasma viral RNA from four M31 mice at 10 weeks p.i. Escape mutations in the Rev, Nef and Vpu epitopes were observed in each of the M31 mice, while no evolution was observed in any of the three Gag epitopes. The Vpu region has not been previously described as a targeted epitope, but is predicted to bind HLA-B*57 (SYFPEITHI, Marsh 2000).

Figure 6.

HLA-B*57-positive mice exhibit enhanced control of viral replication. *Open circles* denote viral loads (mean RNA copies/ml plasma $\pm$ SEM) from four groups of mice that do not express protective HLA alleles (the number of mice at each per time point, in order, are : 32, 28, 19, 16, 14, 14). *Closed squares* denote viral loads from two groups of mice expressing HLA-B*57 (the number of mice at each time point, in order, are: 12, 12, 12, 9, 9, 8), which exhibited significantly lower viral loads at and beyond 6 weeks of infection (* $p < 0.03$ for B*57 for both groups when combined or compared separately by Wilcoxon-Mann-Whitney).

Table 1

Genetic background and HLA haplotypes of humanized BLT mice.

Group ¹	Genetic 2 Background	# Mice	HLA-A*	HLA-B*	HLA-C*
<u>M16</u>	NS	1	01:01	35:02	49:01 04:01 07:01
<u>M20</u>	NS	6	01:01	02:01	08:01 52:01 03:03 07:01
<u>M24</u>	NS	8	02:01	26:01	15:01 27:05 01:02 03:04
<u>M30</u>	NS	7	01:01	01:01	08:01 08:01 07:01
<u>M31</u>	NSG	6	24:02	74:00	14:02 57:03 02:02 06:02
<u>M33</u>	NSG	1	02:01	24:03	N.D. N.D. 03:03 07:02
<u>M47</u>	NSG	7	02:06	24:02	15:02 40:01 03:04 04:03
<u>M51</u>	NSG	6	03:01	11:01	35:01 57:01 04:01 06:02

¹ Each group of mice reconstituted with a single human donor's tissues and cells is designated by a group number, e.g. M20; individual mice are further designated with a dash followed by the mouse number, e.g. M20-07.

² NS = NOD/SCID, NSG = NOD/SCID/IL2RγC^{-/-}.

Bold indicates groups from which sequence was examined. Underlined group numbers designate groups from which viral load data was determined. N.D. = not determined.